Evidence map›Paper›PMID 30344351›Full record

ArticleTetrahedron2018

Selective, C-3 Friedel-Crafts acylation to generate functionally diverse, acetylated Imidazo[1,2-

Brendan Frett, Nicholas McConnell, Anupreet Kharbanda, Gunaganti Naresh, Benjamin Rounseville, Christina Warner, John Chang, Natalie Debolske, Hong-Yu Li

Abstract read
In one paragraph

Article in Tetrahedron, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Brendan Frett *Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Nicholas McConnell *College of Pharmacy, Department of Pharmacology and Toxicology, The University of Arizona, 1703 E. Mabel, Tucson, AZ 85721, USA.
Anupreet KharbandaDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Gunaganti NareshDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Benjamin RounsevilleCollege of Pharmacy, Department of Pharmacology and Toxicology, The University of Arizona, 1703 E. Mabel, Tucson, AZ 85721, USA.
Christina WarnerCollege of Pharmacy, Department of Pharmacology and Toxicology, The University of Arizona, 1703 E. Mabel, Tucson, AZ 85721, USA.
John ChangCollege of Pharmacy, Department of Pharmacology and Toxicology, The University of Arizona, 1703 E. Mabel, Tucson, AZ 85721, USA.
Natalie DebolskeCollege of Pharmacy, Department of Pharmacology and Toxicology, The University of Arizona, 1703 E. Mabel, Tucson, AZ 85721, USA.
Hong-Yu LiDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

Funding

The Role o f Tetrahydrobiopterin (BH4) Bioavailability in Radiation-induced Skin InjuryP20GM109005 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI WOLFE, TATIANA · 2015 to 2024
$21.1M
CHEMISTRY-BIOLOGY INTERFACE TRAINING PROGRAMT32GM008804 · NIGMS · UNIVERSITY OF ARIZONA · PI MONTFORT, WILLIAM R. · 2003 to 2023
$3.9M
Selective RET Kinase and Its Mutant Inhibitors for the Treatment of Medullary Thyroid CancerR01CA197178 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI LI, HONG-YU, MCDONALD, NEIL · 2015 to 2019
$1.5M
Discovery and Development of a Selective pan-FLT3-ITD Kinase Inhibitor Clinical Candidate for the Treatment of FLT3-ITD-Driven AMLR01CA194094 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI LI, HONG-YU, SHAH, NEIL P · 2015 to 2018
$1.5M
NCI NIH HHS R01 CA194094NCI NIH HHS R01 CA197178NIGMS NIH HHS P20 GM109005NIGMS NIH HHS T32 GM008804
6 · The paper itself

Abstract

Carbon-carbon bonds are integral for pharmaceutical discovery and development. Frequently, C-C bond reactions utilize expensive catalyst/ligand combinations and/or are low yielding, which can increase time and expenditures in pharmaceutical development. To enhance C-C bond formation protocols, we developed a highly efficient, selective, and combinatorially applicable Friedel-Crafts acylation to acetylate the C-3 position of imidazo[1,2-

Indexed as

Combinatorial chemistryDrug discoveryFriedel-Crafts acylationImidazo[1,2-a]pyridineLibrary generation

Identifiers

PMID30344351
PMCPMC6192254

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.